All In Biotech

Drug Trial Radar · NCT06481488

A Study of E2086 in Healthy Adult Participants

A Randomized, Double-Blind, Placebo-Controlled, Combined Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Single Dose Study to Assess Food Effect of E2086 in Healthy Adult Subjects

Last checked: Nov 19, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Jun 25, 2024

Primary completion

Dec 13, 2024

Study completion Dec 13, 2024

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jul 1, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety and tolerability following multiple ascending doses of E2086 in healthy adult participants.

Conditions

  • Healthy Volunteers

Interventions

  • E2086Drug

    E2086 tablets.

  • PlaceboDrug

    E2086 matched placebo tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Day 10
  2. Part A: Number of Participants With Serious Adverse Events (SAEs)Time frame: Day 10
  3. Part A: Number of Participants With Clinically Significant Abnormal Laboratory ParametersTime frame: Day 10
  4. Part A: Number of Participants With Clinically Significant Abnormal Vital Signs ValuesTime frame: Day 10
  5. Part A: Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) FindingsTime frame: Day 10
  6. Part A: Number of Participants With Clinically Significant Abnormal Electroencephalogram (EEG) FindingsTime frame: Day 8
  7. Part A: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-suicide Severity Rating Scale (C-SSRS)Time frame: Day 10
  8. Part B: Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRSTime frame: Day 7

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Parexel International

    Glendale, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.